Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20634961 | 0.87 | CA1 (0.35) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL24458096 | 0.82 | PDE2A (0.32) | — | |
| SCHEMBL19682788 | 0.82 | — | — | |
| SCHEMBL12329570 | 0.81 | LMNA (0.33) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL10304726 | 0.81 | TRPM8 (0.38) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL13377468 | 0.79 | LMNA (0.32) | LMNATRPA1CHRM1SLC6A2ADRA1A | |
| SCHEMBL21603341 | 0.77 | ALDH1A1 (0.37) | LMNAPOLBGAAGFER | |
| SCHEMBL20634318 | 0.77 | GABRA1 (0.35) | LMNA | |
| SCHEMBL2737199 | 0.77 | LMNA (0.39) | LMNA | |
| SCHEMBL17125232 | 0.77 | LMNA (0.39) | LMNACHRM1ADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-06 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-12-03 | — | — | US | disclosed |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | LMNA 3453/4885TRPA1 971/4885CHRM1 2187/4885 |
| US-20230212207-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OTC, OCIAD1 | LMNA 1825/4885TRPA1 132/4885CHRM1 569/4885 |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | ALDH1A2, ODC1, NDUFS2 | LMNA 3971/4885TRPA1 297/4885CHRM1 799/4885 |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | LMNA 3932/4885TRPA1 83/4885CHRM1 573/4885 |
| US-20100102710-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ODC1, AOX1, OR10J3 | LMNA 3954/4885TRPA1 42/4885CHRM1 462/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | LMNA 4438/4885TRPA1 4247/4885CHRM1 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.